Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Regorafenib

Stivarga

Stage Approved

Sponsor Bayer

Route oral tablet

Modality small molecule

Class multi-kinase TKI

Mechanism kinase inhibitor; label boxed warning for hepatotoxicity

Target KIT (TEC-0117)

Target VEGFR

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=824f19c9-0546-4a8a-8d8f-c4055c04f7c7

Median PFS in months (95% CI) 4.8 (3.9, 5.7) 0.9 (0.9, 1.1) HR (95% CI) 0.27 (0.19, 0.39) ... Median OS in Months 17.4 (14.9, 20.2) 17.4 (12.3, 21.0) HR 0.91

Stivarga USPI boxed warning (hepatotoxicity) and section 14.2, Table 8, GRID (NCT01271712)

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT01271712

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

GRID

Registry NCT01271712

Phase Phase 3

Status Completed

Enrollment 199

Start 2011-01-04

Primary completion 2012-01-26

Study completion 2019-04-15

Regorafenib 160 mg, 3 weeks on 1 off

Dose 160 mg

Regimen once daily, days 1 to 21 of 28

Comparator placebo

Population GIST after imatinib and sunitinib

Estimand ITT

median progression-free survival: 4.8 months, primary analysis

progression-free survival hazard ratio vs placebo: 0.27 HR, primary analysis

median overall survival: 17.4 months, final OS analysis, 162 events

Placebo

Dose placebo

Regimen days 1 to 21 of 28

Population GIST after imatinib and sunitinib

Estimand ITT

median progression-free survival: 0.9 months, primary analysis

median overall survival: 17.4 months, final OS analysis; 88% crossed over